Japan Tissue Engineering (7774) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The key takeaway from this earnings report is that the operating loss expanded substantially year on year due to the combination of declining revenue and a higher SG&A ratio. Revenue was ¥15.1B (-11.5% YoY), Operating Income was ¥-5.6B (a ¥2.3B deterioration from ¥-3.3B in the prior year), Ordinary Income was ¥-5.5B (compared with ¥-3.3B in the prior year), and Net Income was ¥-5.6B (compared with ¥-3.5B in the prior year). The primary factors behind the revenue decline were a decrease in the number of JACE (burn treatment) cases in the core regenerative medicine products business and the postponement of monetization for certain projects in the regenerative medicine contract business to the next fiscal year.

Factors Affecting Results

【Revenue】Revenue was ¥15.1B, down -11.5% year on year. In the regenerative medicine products business, which has the largest revenue mix, the decline in the number of JACE burn cases had a significant impact. In the regenerative medicine contract business, the loss of one-time revenue from a specific customer recorded in the previous period and the postponement of the Teijin contract milestone to the next fiscal year were factors behind the decline. Meanwhile, the LabCyte business secured revenue growth of +20.3% year on year, driven by expanded recurring purchases in Europe and the United States.

【Profit and Loss】The gross profit margin deteriorated from the prior year to 55.4%, while the SG&A ratio rose to 92.7%, resulting in an operating loss of ¥5.6B. Ordinary Loss of ¥5.5B and Net Loss of ¥5.6B were nearly in line with the operating loss, and no unusual one-time gains or losses were identified. This was an earnings report characterized by lower revenue and wider losses, with the burden of fixed costs being the primary cause of the loss expansion.

Segment Analysis

The regenerative medicine products business was the core business, with revenue of ¥9.6B and a revenue mix of 63.4%; profitability was thin, with Operating Income of ¥0.1B and a profit margin of 0.6%. The decline in JACE cases had the largest impact on the overall revenue decrease. The custom development and contract manufacturing business generated revenue of ¥3.5B, Operating Income of ¥1.9B, and a profit margin of 53.6%, making it the most profitable segment and a significant contributor to overall profit. The LabCyte business generated revenue of ¥2.1B, Operating Income of ¥0.5B, and a profit margin of 22.4%, maintaining its revenue growth trend. The differences in profit margins among the segments are substantial, creating a structure in which the low profitability of the core regenerative medicine products business leads to an overall operating loss.

Key Financial Metrics

ROE was -14.1% on an annualized basis, deteriorating year on year, while the operating margin was -37.3%. The Equity Ratio was high at 89.4%, indicating strong financial soundness. Current assets were ¥41.3B versus current liabilities of ¥5.9B, resulting in a current ratio of over 700%. Cash and deposits of ¥33.4B accounted for 56.7% of total assets, indicating ample near-term financial capacity.

Cash Flow Analysis

As cash flow details were not included in the disclosed data, cash flow statement items cannot be presented. Cash and deposits were ¥33.4B, down from ¥38.9B in the prior year, suggesting that cash consumption from operating losses may be progressing. Financial soundness remains high, with an Equity Ratio of 89.4% and a debt-to-equity ratio of 0.12x, indicating low dependence on external debt.

Quality of Earnings

Ordinary Loss of ¥5.5B and Net Loss of ¥5.6B were nearly at the same level, with only a small gap between the two and a limited impact from extraordinary gains and losses. Non-operating income was ¥0.1B, equivalent to only 0.7% of revenue, indicating no dependence on non-operating income. The losses resulted from deteriorating profitability in the core business at the operating level. In terms of earnings quality, the results confirm a structurally operating loss-making business rather than earnings being inflated by temporary factors.

Earnings Forecast and Guidance

Against the full-year revenue forecast of ¥22.1B, the Q3 cumulative progress rate was 68.3%, below the standard progress rate of 75%. Against the full-year operating loss forecast of ¥5.5B, the Q3 cumulative operating loss was already ¥5.6B, exceeding the plan. Net Loss was also ¥5.6B versus the forecast of ¥5.4B, likewise exceeding the plan. The company has set achieving profitability next fiscal year as its new target and expects JACE OA indication expansion to contribute to revenue in Q4. However, based on the progress to date, substantial earnings improvement in Q4 is a prerequisite.

Shareholder Returns

The Q2 dividend was ¥0, representing no dividend. The full-year dividend forecast is also ¥0, and the Payout Ratio is not calculable (effectively 0%). No share repurchases have been identified while Net Losses continue. The no-dividend policy is consistent with a stance that prioritizes preserving cash and equity.

Catalysts

【Short Term】Expansion of sales following reimbursement coverage associated with the expanded JACE OA indication (launched in January 2026, with 52 eligible facilities) is expected to be reflected in revenue from Q4 onward.

【Long Term】Expansion of Jasmine locations (11 facilities), consideration of establishing a European base for the LabCyte business, submission of an approval application for Allo-JaCE03 within the fiscal year, and a commercial production agreement with AlliedCel in the regenerative medicine contract business are expected to contribute to building the medium- to long-term earnings base.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability is substantially below the industry median and is at a level markedly underperforming the manufacturing industry average.

Growth and Capital Efficiency

The revenue growth rate is also below the industry median, positioning the company within the industry as one experiencing a phase of declining revenue.

※Source: Compiled by the Company

Risk Factors

1. Revenue Progress Risk: Progress toward the full-year revenue forecast was 68.3%, below the standard progress rate of 75%. Revenue of approximately ¥7.0B will be required in Q4, necessitating acceleration above the Q3 cumulative quarterly average.

2. Profitability Deterioration Risk: The SG&A ratio reached 92.7%, and the gap versus the gross profit margin of 55.4% is expanding the operating loss. If the decline in JACE cases continues, insufficient absorption of fixed costs may persist.

3. Project Monetization Timing Risk: In the regenerative medicine contract business, the Teijin contract milestone has been pushed back to the next fiscal year, creating a structure in which the timing of revenue recognition from contract projects affects results.

Key Earnings Takeaways

1. Q3 cumulative Operating Loss and Net Loss have already exceeded the full-year forecasts, highlighting the potential for earnings improvement in Q4 based on the earnings data.

2. The core regenerative medicine products business, which accounts for 63.4% of the revenue mix, has low profitability at 0.6%, whereas the custom development and contract manufacturing business has high profitability at 53.6%, confirming differences in the earnings structure within the business portfolio.

3. The high level of financial soundness, reflected in an Equity Ratio of 89.4% and a current ratio of over 700%, indicates that short-term funding constraints remain limited despite continuing operating losses.

Theoretical Share Price (Reference Value)

Sensitivity: ¥65–¥69 at a ±1% change in the cost of equity, and ¥65–¥68 at a ±0.1 change in ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference versus the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI through integrated analysis of XBRL earnings flash data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---